Meizhimiao

Shanghai Meizhimiao Biotechnology (Meizhimiao) is a clinical-stage synthetic biology company dedicated to the development of high-performance biomaterials for medical aesthetics and regenerative medicine. Founded in 2021, the company utilizes a proprietary synthetic biology platform to design and manufacture humanized recombinant proteins with superior biocompatibility and efficacy. Its lead product, MZM-001, is a recombinant humanized Type III collagen currently in clinical development for aesthetic indications such as the correction of facial wrinkles and nasolabial folds. Backed by top-tier investors including Sequoia China, GL Ventures, and Matrix Partners China, Meizhimiao is positioned as a leader in the next generation of bio-based aesthetic treatments.